Allos AI

To add a bio or update company history, please click update information.

News from Allos AI

Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs

13 Jan 2026

Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs

Allos AI applies causal AI to reformulate complex generic drugs, improving delivery, tolerability and predictability while reducing development uncertainty.

Life Sciences
Oxford, United Kingdom
£4m
allos.ai
Update Information

More venture news

CN Bio
12 Aug 2026
CN Bio secures a £180k Innovate UK grant to develop organ-on-a-chip system for drug behaviour predictions
GrantLife Sciences
Mironid
5 Aug 2026
Mironid raises a £34m Series B including £8.4m from Scottish National Investment Bank to advance small molecule treatments for kidney diseases
Series BLife Sciences
Qureight
29 Jul 2026
Qureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease
Series BLife Sciences

Allos AI

News from Allos AI

Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs

More venture news

CN Bio secures a £180k Innovate UK grant to develop organ-on-a-chip system for drug behaviour predictions

Mironid raises a £34m Series B including £8.4m from Scottish National Investment Bank to advance small molecule treatments for kidney diseases

Qureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease